Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | 4:持股变动声明-董事 Flynn James E
Larimar Therapeutics | 4:持股变动声明-董事 Hamilton Thomas Edward
Larimar Therapeutics | 4:持股变动声明-董事 Truitt Joseph
Larimar Therapeutics | 4:持股变动声明-董事 SHERMAN JEFFREY W
Larimar Therapeutics | 4:持股变动声明-董事 LEFF JONATHAN S
Larimar Therapeutics | 4:持股变动声明-董事 THOMAS FRANK E
Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | EFFECT:其他
Larimar Therapeutics | CORRESP:信函
Larimar Therapeutics | 8-K:重大事件
Larimar Therapeutics | UPLOAD:其他
Larimar Therapeutics | S-3:特定交易注册声明
Larimar Therapeutics | 10-Q:季度报表
Larimar Therapeutics | 8-K:Larimar Therapeutics公布2024年第一季度运营和财务业绩
Larimar Therapeutics | ARS:年度报告
Larimar Therapeutics | DEF 14A:股东委托书决议
Larimar Therapeutics | PRE 14A:并购重组委托声明
Larimar Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-Deerfield Management Company, L.P.(33.32%),James E. Flynn(33.32%)等
暂无数据